Analysts Set Halozyme Therapeutics Inc. (HALO) Price Target at $15.54
Halozyme Therapeutics Inc. (NASDAQ:HALO) has been given an average rating of “Buy” by the eight research firms that are currently covering the firm. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $13.96.
Several brokerages recently commented on HALO. Jefferies Group restated a “sell” rating and set a $6.75 target price on shares of Halozyme Therapeutics in a research report on Tuesday, November 8th. Deutsche Bank AG started coverage on Halozyme Therapeutics in a report on Thursday, November 3rd. They issued a “buy” rating and a $12.00 price target on the stock. Piper Jaffray Cos. increased their price target on Halozyme Therapeutics from $15.00 to $18.00 and gave the stock an “overweight” rating in a report on Friday, September 16th. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, September 8th.
Halozyme Therapeutics (NASDAQ:HALO) opened at 12.83 on Monday. Halozyme Therapeutics has a 52 week low of $6.96 and a 52 week high of $18.39. The company’s market capitalization is $1.64 billion. The stock’s 50 day moving average price is $10.67 and its 200 day moving average price is $10.01.
Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.04. Halozyme Therapeutics had a negative return on equity of 405.28% and a negative net margin of 44.60%. The company had revenue of $31.90 million for the quarter, compared to analyst estimates of $34.43 million. During the same quarter in the prior year, the company earned ($0.19) EPS. The firm’s revenue for the quarter was up 53.4% compared to the same quarter last year. Analysts anticipate that Halozyme Therapeutics will post ($0.87) earnings per share for the current year.
Several hedge funds have recently modified their holdings of the company. Commonwealth Equity Services Inc bought a new stake in shares of Halozyme Therapeutics during the second quarter valued at approximately $109,000. BNP Paribas Arbitrage SA increased its stake in shares of Halozyme Therapeutics by 113.7% in the third quarter. BNP Paribas Arbitrage SA now owns 9,051 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 4,815 shares during the period. Amalgamated Bank increased its stake in shares of Halozyme Therapeutics by 3.0% in the second quarter. Amalgamated Bank now owns 11,518 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 338 shares during the period. Royal Bank of Canada increased its stake in shares of Halozyme Therapeutics by 13.5% in the second quarter. Royal Bank of Canada now owns 14,200 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 1,685 shares during the period. Finally, Parametrica Management Ltd bought a new stake in shares of Halozyme Therapeutics during the third quarter valued at approximately $131,000. 80.62% of the stock is owned by hedge funds and other institutional investors.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.
Receive News & Stock Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related stocks with our FREE daily email newsletter.